Wang Lai 4

What Happened
Wang Lai, President and Global Head of R&D at BeOne Medicines (ONC), was granted two awards on 2026-03-06 totaling 167,635 ordinary shares (112,606 and 55,029). Both grants are reported as acquisitions at $0.00 (award/compensation), i.e., performance share units rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-03-06; Form 4 filed 2026-03-10 (filed within required business-day window).
• Grants: 112,606 shares (footnote F1) and 55,029 shares (footnote F2); aggregate = 167,635 shares; reported price $0.00.
• Vesting: F1 award vests in 2027; F2 award vests in 2028, each subject to continued service and possible accelerated vesting on certain termination events.
• Shares owned after transaction: not specified in the filing.
• Other notable disclosures: Securities held via Wang Holdings LLC (F3) and participation in an RMB Shares Employee Participation Plan (F4–F6); Wang disclosed a RMB10M contribution to the plan but disclaims beneficial ownership of the plan’s shares beyond any pecuniary interest.

Context
These were compensation awards (performance share units) rather than purchases or sales—common for executive pay and not an immediate market signal. The units vest in future years if service conditions are met; unvested awards may accelerate under certain termination scenarios.